Natco Pharma Ltd. News and Updates

Name: Latest research reports of Natco Pharma Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Natco Pharma Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on Natco Pharma Ltd. from all sources in a single place.

Load latest

Natco Pharma Ltd.

19 Oct 2020

854.65

-1.14%

Multiple growth catalysts falling in place for Natco Pharma: Analysts

Business Standard

Strong impetus to exports by a mega product launch in North America and business outside the US bode well for earnings

Natco Pharma Ltd. has an average target of 1294.50 from 4 brokers.

Natco Pharma Ltd.

15 Oct 2020

854.65

-1.14%

Natco Pharma eyes launch of 8-10 new drugs yearly in Indian market

Business Standard

Natco Pharma aims to launch around 10 new products every year in the Indian market, the city-based drug maker said on Thursday

Number of MF schemes decreased from 54 to 47 in Jun 2025 qtr

Natco Pharma Ltd.

04 Oct 2020

854.65

-1.14%

Stock query: Natco Pharma on medium-term uptrend

Business Line

But the stock faces a significant resistance ahead at 1,000

Natco Pharma Ltd.'s price crossed below 30Day SMA today

Natco Pharma Ltd.

21 Sep 2020, 03:35PM

854.65

-1.14%

Natco Pharma aims to diversify product portfolio in domestic market

Moneycontrol

New Delhi, Sep 21 Natco Pharma plans to diversify its product portfolio in the domestic market as it aims to make up for a drop in business of some..

Natco Pharma Ltd. has lost -42.30% in the last 1 Year

Natco Pharma Ltd.

18 Sep 2020

854.65

-1.14%

Buy Natco Pharma: target of Rs 954: ICICI Securities

Moneycontrol

ICICI Securities is bullish on Natco Pharma recommended buy rating on the stock with a target price of Rs 954 in its research report dated September 18, 2020.

Natco Pharma Ltd. has lost -42.30% in the last 1 Year

Natco Pharma Ltd.

10 Sep 2020

854.65

-1.14%

Natco Pharma to make Time Cap Overseas a wholly-owned arm

Business Line

This will be all-cash transaction

Geojit BNP Paribas decreased Hold price target of Natco Pharma Ltd. to 940.0 on 17 Sep, 2025.

Natco Pharma Ltd.

14 Aug 2020

854.65

-1.14%

NATCO PHARMA

Hold: Natco Pharma Ltd.

Recommendation Target

Geojit BNP Paribas

NATCO Pharma (NATCO) is a R&D; focussed, vertically integrated pharmaceutical company with an experienced management team and presence across multiple speciality therapeutic segments. We upgrade our rating from Sell to Hold by valuing Natco at 26x FY22 EPS with a target of Rs.881. We expect the combination of existing products such as Chloroquine, Oseltamivir as well as the launch of Revlimid in the U.S and its focus on other regulated markets to drive overall profitability. Total revenues were up 13% YoY during the quarter led by strong performance in the export formulation and API segments. Formulation exports grew by 29% YoY, led by strong showing in...

Natco Pharma Ltd. has an average target of 1294.50 from 4 brokers.

Natco Pharma Ltd.

13 Aug 2020

854.65

-1.14%

Natco Pharma Limited

Buy: Natco Pharma Ltd.

Target

ICICI Securities Limited

Natco has carved out its own identity via tie-ups to tap limited but niche products pipeline including 20 Para IVs filings (FY20). As per the revised and more feasible game plan, it plans to market products via tie-ups with established players in the generic space. Till FY19, the company had filed 51 ANDAs, which includes some niche FTF opportunities. Overall, the...